ALKS Alkermes plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALKS

Price (delayed)

$24.29

Market cap

$4.05B

P/E Ratio

18.83

Dividend/share

N/A

EPS

$1.29

Enterprise value

$3.79B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
The EPS has soared by 111% since the previous quarter
Alkermes's net income has soared by 108% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: ACOR BMY JNJ PFE

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
166.88M
Market cap
$4.05B
Enterprise value
$3.79B
Valuations
Price to earnings (P/E)
18.83
Price to book (P/B)
2.98
Price to sales (P/S)
2.54
EV/EBIT
15.84
EV/EBITDA
12.02
EV/Sales
2.38
Earnings
Revenue
$1.59B
EBIT
$239.32M
EBITDA
$315.38M
Free cash flow
$254.12M
Per share
EPS
$1.29
Free cash flow per share
$1.53
Book value per share
$8.14
Revenue per share
$9.55
TBVPS
$13.06
Balance sheet
Total assets
$2.28B
Total liabilities
$923.65M
Debt
$384.98M
Equity
$1.36B
Working capital
$961.67M
Liquidity
Debt to equity
0.28
Current ratio
2.91
Quick ratio
2.44
Net debt/EBITDA
-0.83
Margins
EBITDA margin
19.8%
Gross margin
85.1%
Net margin
13.5%
Operating margin
13.5%
Efficiency
Return on assets
10.3%
Return on equity
18.3%
Return on invested capital
17.3%
Return on capital employed
13.5%
Return on sales
15%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
0.62%
1 week
-0.41%
1 month
-1.02%
1 year
-3.61%
YTD
-7.04%
QTD
-13.28%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.59B
Gross profit
$1.35B
Operating income
$214.97M
Net income
$214.72M
Gross margin
85.1%
Net margin
13.5%
Alkermes's net income has soared by 108% from the previous quarter
Alkermes's operating income has soared by 95% from the previous quarter
The net margin has soared by 93% from the previous quarter
The company's operating margin has surged by 78% QoQ

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
ALKS P/E details
P/E
18.83
P/B
2.98
P/S
2.54
EV/EBIT
15.84
EV/EBITDA
12.02
EV/Sales
2.38
The EPS has soared by 111% since the previous quarter
The company's equity rose by 30% YoY and by 6% QoQ
The P/B is 27% lower than the last 4 quarters average of 4.1 and 17% lower than the 5-year quarterly average of 3.6
The revenue has grown by 41% YoY and by 9% from the previous quarter
ALKS's P/S is 29% below its last 4 quarters average of 3.6 and 25% below its 5-year quarterly average of 3.4

Efficiency

How efficient is Alkermes business performance
The ROA has soared by 102% QoQ
The ROIC has soared by 99% from the previous quarter
The return on equity has surged by 95% since the previous quarter
The ROS has soared by 79% since the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 147% higher than its total liabilities
ALKS's quick ratio is up by 37% year-on-year and by 2.1% since the previous quarter
The current ratio has grown by 30% YoY
The debt is 72% less than the equity
The company's equity rose by 30% YoY and by 6% QoQ
The debt to equity is down by 28% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.